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Objective: The aim of this study was to identify factors associated with the development ofgraft stenoses in the first year 
after bypass. 
Design and setting: Between January 1992 and April 1993, 75 consecutive patients undergoing distal vein bypass 
surgery were entered into a graft surveillance programme at Charing Cross Hospital. The grafts (n = 79) were surveyed by 
colour flow Doppler ultrasonography at7 days, 3, 6, 9 and 12 months and the site of stenoses ( > 50%) recorded. Position 
of the distal anastomosis, graft type (in situ or reverse) and clinical history were recorded. At the 3-month surveillance a 
blood sample was taken for the estimation of smoking markers, lipids and fibrinogen. 
Results" The site of the distal anastomosis was to the suprageniculate popliteal in nine, infrageniculate popliteal in 32 and 
tibio/peroneal vessels in 38 cases. In the first month following bypass there were six deaths, giving a 30 day mortality of 
7.5%, three patients were lost to follow up, seven grafts occluded, three were replaced by PTFE, four patients underwent 
amputation and one patient had a redo vein graft. In the remaining rafts 20/63 (32%) developed stenoses within the first 
year after bypass. The development of a graft stenosis was not associated with sex, diabetic status, site of distal anastomosis, 
graft type or serum lipids. Multiple regression analysis identified only one factor associated significantly with the 
development ofvein graft stenosis: fibrinogen concentration (p = 0.003). Life table analysis showed that after i year only 
46% of grafts remained free of stenoses in patients with above median fibrinogen concentrations compared with 84% of 
grafts in patients with below median fibrinogen concentrations, p = 0.009. 
Conclusions: Increased plasma fibrinogen concentration is a potent risk factor for the development ofvein graft stenosis. 
These results prompt consideration ofthe role of fibrinogen in stimulating smooth muscle cell proliferation in the stenotic 
lesion. 
Key Words: Fibrinogen; Smoking; Graft stenoses; Intimal hyperplasia. 
Introduction 
Autologous vein is the best conduit for distal bypass 
grafting, particularly where the distal anastomosis is 
below the knee. l"a Over 20 years ago the classic paper 
of Szilagyi and colleagues outlined the biological fate 
of autogenous vein grafts in the femorodistal circula- 
tion. 3 Graft failure within the first month after bypass 
has been attributed to technical failures or poor 
patient selection. Graft failure between 1 and 12 
months after bypass has been attributed to perianasto- 
motic intimal hyperplasia, localised graft stenoses and 
strictures and graft thrombosis. Up to 30% of vein 
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grafts develop localised stenoses or strictures in the 
first 12 months after bypass. 4"5 Early detection and 
treatment of these lesions has improved the long term 
patency rate of vein grafts. B'6 Hence graft surveillance 
programmes have been advocated as cost-effective, 
particularly since the widespread availability and 
diagnostic potential of Duplex scanning permits reli- 
able, non-invasive surveillance of distal vein bypass 
grafts. Pharmacologic treatment to minimise anasto- 
motic and intimal hyperplasia has also been con- 
sidered. 7 Currently no pharmacologic therapy has 
been successful in improving the patency of distal 
vein grafts and an improved understanding of intimal 
hyperplasia nd other pathological processes under- 
lying the development of graft stenoses i essential to 
the development of new therapeutic strategies. 2"7 
Previous work has shown that both smoking and 
increased plasma fibrinogen concentrations adversely 
1078-5884/95/040415 + 06 $08"00/0 © 1995 W. B. Saunders Company Ltd. 
416 R.C.J .  Hicks et aL 
influence the patency of femoropopliteal vein grafts. 8
Here we have investigated, in a prospective stud)4 
how smoking and plasma factors influence the devel- 
opment of vein graft stenoses. Subsequently we have 
initiated in vitro studies to investigate how increased 
concentrations of plasma fibrinogen could stimulate 
the pathological processes underlying the develop- 
ment of vein graft stenoses. Our findings are reported 
here. 
Patients and Methods 
Between January 1992 and April 1993, 75 consecutive 
patients undergoing infrainguinal vein bypass grafts 
(n = 79) were entered into a graft surveillance pro- 
gramme. These patients included 48 men and 27 
women, age range 47-93, with a median of 70 years. 
At the time of surger~ 22 patients were diabetic, and 
27 were current smokers. Surgery was performed by 
one of the two consultant surgeons at the Regional 
Vascular Service at Charing Cross Hospital in all but 
three cases, these having been performed by the 
vascular Senior Registrar. The indications for surgery 
were categorised as critical ischaemia, incapacitating 
claudication, with a claudication distance of < 50m 
and popliteal aneurysm. The upper anastomosis was 
to the common femoral or superficial femoral artery in 
all 79 operations performed. The lower anastomosis 
was to the suprageniculate popliteal artery in nine 
cases, to the infrageniculate popliteal artery in 32 cases 
and distal to the popliteal artery in 38 cases. In-situ 
bypass grafts were used for 33 reconstructions and 
reverse vein grafts in 46 reconstructions. A composite 
graft using a combination of autologous vein graft and 
PTFE was required in two patients because of inade- 
quate availability of autologous vein. 
Graft surveillance was by colour flow Doppler 
ultrasonography (Duplex scanning) using an ATL 
Ultramark 9 HDI, (Bothel, Washington, U.S.A.). The 
entire length of the graft was scanned including the 
proximal and distal anastomoses. Details of the 
character of the wave form and the peak systolic 
velocity were recorded at three points along the graft. 
Doubling of the post-stenotic flow velocity at a 
particular point in the graft relative to the flow 
velocity at a point 2 cm from the stenosis has been 
considered to denote a stenosis of 50%. 9 Greater 
degrees of stenosis were signified by higher graft flow 
velocities and were estimated from both the increase 
in flow velocity and a narrowing of the lumen. Where 
there was a less than two-fold increase in flow velocity 
at a particular point a stenosis of < 50% was indicated, 
but the degree of stenosis could not be estimated 
reliably. Haemodynamically significant stenoses of 
50-70% were noted and patients kept under close 
observation. Stenoses of greater than 70%, where the 
post-stenotic flow velocity had increased > 4 fold, 
were referred to the clinical team for possible inter- 
vention. Grafts were monitored at 7 days, 3, 6, 9 and 12 
months. At each visit the resting ankle/brachial 
pressure index (ABPI) was recorded together with the 
assessment of pulses and clinical symptoms. 
At the 3 and 12 month surveillance, a blood 
sample was obtained for estimation of smoking 
markers, triglycerides and fibrinogen. Cotinine, the 
principal long-lived metabolite of nicotine, and car- 
boxyhaemoglobin were used as smoking markers. 
Cotinine concentrations were determined using gas 
liquid chromatography. 1° Cotinine levels of >200 
nmol/1 and carboxyhaemoglobin levels of > 2% were 
considered indicative of current smoking. Fibrinogen 
was measured using an end-point immunonephelo- 
metric assay with an interassay coefficient variation of 
5%.8 
Statistical analyses 
Graft survival was assessed using life table analysis 
with significance being calculated by the log rank 
method. Multiple logistic regression was conducted to 
assess which factors were most closely associated with 
vein graft failure. A stepwise backwards elimination 
procedure was used (p--0.2 for terms to drop out of 
the model). The association of individual variables 
with graft stenosis was assessed by either a Mann- 
Whitney U-test or •2 analysis. 
Results 
The indications for distal bypass surgery included 
popliteal aneurysm (10 grafts), critical ischaemia (56 
grafts) and incapacitating claudication, with a claudi- 
cation distance of 50 m or less (13 grafts). The ABPI 
according to presentation is shown in Fig. 1. In this 
figure open symbols have been used to identify 
diabetic patients, in whom 23 grafts were performed. 
The three remaining patients presenting with either 
claudication or critical ischaemia nd having an ABPI 
~_ 0:6 all had heavily calcified, incompressible 
vessels. 
In the first month there were six deaths, giving a 
30 day mortality of 6/79 (7.5%); there were no 
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simultaneous bilateral reconstructions. A further 
seven patients occluded their grafts in the first month: 
three patients had a prosthetic graft replacement, three 
patients underwent below-knee amputation and one 
patient underwent above-knee amputation. One fur- 
ther patient developed a severe ( > 90%) stenosis at the 
proximal anastomosis and underwent secondary 
reconstruction with autologous vein. Two patients 
relocated and were lost to follow up in the first month. 
All these patients/grafts were excluded from sub- 
sequent analysis of factors associated with vein graft 
stenosis, leaving 59 patients, with 63 grafts, to con- 
tinue in the surveillance programme. None of these 63 
grafts were observed to have stenoses 1 week follow- 
ing reconstruction. 
Between 1 and 12 months after bypass surgery 
three further patients died, one refused follow-up and 
three others were lost to follow-up. Two patients 
missed the 3-month surveillance but returned to the 
surveillance programme before the end of the year. At 
the end of 12 months, 36 vein grafts were known to be 
free of stenoses and stenoses had developed in 20 
grafts. Most stenoses (n = 10) developed in the first 3 
months after bypass, six at the distal and four at the 
proximal anastomosis. At 6 months a further four 
stenoses were detected, four stenoses at 9 months and 
two at 12 months. The cumulative survival of the vein 
grafts, free of stenosis, is shown in Fig. 2. The stenoses 
were found in the proximal and distal regions, within 
2 cm of the anastomosis, of the graft with equal 
frequency; only one stenosis was identified in the mid- 
graft region. The sequelae of the stenoses are shown in 
Table 1. 
Multivariate analysis immediately identified an 
increased fibrinogen concentration as the most sig- 
nificant factor associated with the development of 
vein graft stenosis, p = 0.008. The level of the distal 
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Fig. 1. Indications for vein bypass surgery and ankle/brachial 
pressure index. (C)) Patients with diabetes; (A) other patients. 
anastomosis, ex, diabetes, preoperative smoking his- 
tory, HDL-cholesterol and cholesterol were not asso- 
ciated with vein graft stenosis and were removed in 
the stepwise elimination of variables. The variables 
remaining in the model included age, in situ or reverse 
vein, carboxyhaemoglobin at 3 months, fibrinogen 
and ABPI at presentation. Of these, graft type was 
eliminated next and results for remaining variables are 
shown in Table 2. Increased fibrinogen concentration 
was the most significant variable associated with the 
development of vein graft stenosis. There was also a 
tendency for stenoses to develop in older patients and 
those with a higher ABPI at presentation. The associa- 
tion between carboxyhaemoglobin (at 3 months) and 
graft stenosis failed to achieve significance, even on 
univariate regression analysis, p = 0.056. For grafts in 
patients with an above median fibrinogen concentra- 
tion (>4.4g/1) life-table analysis demonstrated that 
only 46% remained free of stenoses after one year 
compared with 84% in those with below median 
fibrinogen concentration, p = 0.009 (Fig. 3). A compar- 
ison of the factors studied, for the 20 grafts with 
stenoses and the 36 grafts that remained free of 
stenosis at 1 year, is shown in Table 3. 
Discussion 
The aetiological basis of vein graft stenoses is con- 
sidered to be the abnormal proliferation of smooth 
muscle cells. 7 Laboratory studies have indicated that 
growth factors, including platelet-derived growth 
factor and basic fibroblast growth factor, are likely to 
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Fig. 2. Cumulative graft survival without stenosis. Grafts with a 
severe adverse outcome (n = 8) and patients who died in the first 
month (n = 6) have been excluded. The numbers inparentheses r fer 
to the number of grafts entering each time interval. Three patients 
were lost to foUow-up 
in the first month. 
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Table 1. Site, severity and outcome of graft stenoses 
Site of stenosis Degree of stenosis (%) Management Outcome at 1 year 
Distal 50 Angioplasty Clear 
Proximal 95 Observation Occluded at 9 m 
Proximal 75 Angioplasty Died 
Proximal and distal 95 Angioplasty 70% stenoses at 6 m 
Distal 60 Angioplasty Clear 
Proximal 70 Angioplasty Restenosis, vein patch 
Proximal 85 Angioplasty Clear 
Proximal 80 Angioplasty Restenosis, vein patch 
Multiple 99 Observation Mild claudication 
(pre-ocdusion) 
Proximal & 50 Angioplasty Occlusion with claudication 
mid graft 
Distal 80 Angioplasty Clear 
Distal 65 Observation Asymptomatic, 65% stenosis 
Origin 80 Angioplasty Clear 
Proximal 60 Angioplasty Clear 
Proximal 90 Jump graft Clear 
Distal 90 Angioplasty Clear 
Distal 70 Jump graft Clear 
Distal 60 Observation 70% stenosis 
Distal 99 BKA 
*Pre-occlusion 99 Observation Asymptomatic occlusion 
* patient missed surveillance at 6 and 9 months. 
Table 2. Multivariate regression analysis for factors associated 
with the development of vein graft stenosis 
Variable Partial regression coefficient p 
Age 0.013 0.085 
Smoking at 3 months 
(COHb%) 0.060 0.237 
Fibrinogen (g/l) 0.151 0.003 
ABPI 0.640 0.080 
Constant, 3.63; F ratio, 4.74; probability level 0.002. 
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Fig. 3. The influence of fibrinogen on the development of vein graft 
stenoses. The cumulative graft survival, free of stenoses, is shown 
for patients with above median fibrinogen concentration (m) and for 
patients with below median fibrinogen concentration ([~). Eighty- 
six percent of patients with below median fibrinogen concentrations 
had not developed stenoses 
by 1 year compared with 46% of grafts in patients with above 
median concentrations. The numbers in parentheses give the 
number of grafts entering each time inverval. 
Table 3. Factors associated with graft stenosis with in 1 year of 
bypass 
Stenosis No stenosis p 
(n=20) (n=36) 
Median age (years) 71 70 NS 
Males (%) 70 64 NS 
Diabetes (%) 25 25 NS 
Median ABPI at presentation 0.4 0.34 NS 
Indication for surgery 
incapacitating claudication 2 4 
critical ischaemia 13 29 
popliteal aneurysm 5 3 NS 
in-situ grafts (%) 35 42 NS 
site of anastomosis 
suprageniculate 4 3 
infrageniculate 7 14 
distal 9 19 
History of smoking pre-operatively (%) 35 36 NS 
Median COHb (%) at 3 months 1.75 1.65 NS 
Median Hb (g/l) at 3 months 13.35 14.15 NS 
Median cholesterol (mmol/1) 5.8 5.65 NS 
Median HDL (mmol/1) 1.0 1.27 NS 
Median fibinogen (g/l) 4.9 4.08 0.003 
Median COHb at 12 months (%) 1.5 1.6 NS 
Patients who died or who were lost to follow up during the first 
year, have not been included in this analysis. Categorical variables 
have 2 been compared using x tests and continuous variables using 
Mann-Whitney U-tests. 
act as potent mitogens for smooth muscle cell pro- 
liferation following endovascular p ocedures or vas- 
cular reconstruction. ~2--14 
Previously we have demonstrated that both 
smoking and increased plasma fibrinogen concentra- 
tions were associated with increased risk of both 
femoropopliteal vein and prosthetic graft failure, s'15 
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Since both smoking and fibrinogen act to potentiate 
arterial thrombosis we had considered that this was 
the mechanism by which these two factors contributed 
to vein graft failure in the first year after bypass :graft 
thrombosis. Subsequently a study of factors associated 
with carotid restenosis identified smoking as an 
important risk factor for carotid restenosis, where the 
pathology also results from the abnormal proliferation 
of smooth muscle cells. 16 The current study was 
established to investigate whether smoking also influ- 
enced the development of vein graft stenoses. 
In keeping with other studies most of the graft 
stenoses developed within the first 6 months after 
bypass (n=14). Of all the clinical and measured 
variables only the fibrinogen concentration was asso- 
ciated with the development of graft stenoses. The 
association between the development of stenoses and 
an increased age or increased ABPI at presentation just 
failed to achieve significance (Table 2). There was no 
significant association between the smoking markers 
(carboxyhaemoglobin or cotinine) and graft stenosis at 
either 3 or 12 months after bypass. Previous studies 
have demonstrated an association between the long 
half-life smoking marker thiocyanate and the occlu- 
sion of both femoropopliteal vein and prosthetic 
bypasses, over a similar follow-up period, s'~5 How- 
ever, in both these studies plasma fibrinogen was a 
more powerful predictor of graft occlusion, partic- 
ularly for vein grafts. Graft stenoses, left untreated, are 
likely to lead to the failure of vein grafts, but sudden 
occlusion from thrombosis is another cause of graft 
failure. Therefore there may be some differences in the 
risk factors for graft stenosis and graft occlusion. 
Moreover smoking is recognised to increase plasma 
fibrinogen concentration. The weak association 
between smoking and the development of graft 
stenoses may be a consequence of this and even in a 
larger study, smoking may not be an independent risk 
factor. 
Fibrinogen is the final substrate of the coagulation 
cascade and the association between thrombotic graft 
occlusion and increased fibrinogen concentrations 
could be anticipated. The dominant effect of fibrino- 
gen over all other factors, including site of the distal 
anastomosis, type of graft and severity of disease, in 
predicting the development ofvein graft stenoses was 
not anticipated. Neither has fibrinogen been con- 
sidered to be important to the development of intimal 
hyperplasia. 
Fibrinogen and its degradation products have 
been demonstrated to have three effects which could 
promote the development of graft stenoses. First, 
fibrinopeptide B acts as a vasoconstrictor in rabbit 
aorta. 17 Second, there is circumstantial evidence that 
the fibrinopeptides, together with fibrin degradation 
products are mitogenic for cells in the atherosclerotic 
lesion. ~8'19 Third, fibrinogen promotes, in a dose- 
dependent manner, the adhesion of leukocytes and 
macrophages tocultured endothelium. 2° Currently we 
are investigating the influence of fibrinogen on both 
the vasomotor tone and leukocyte adhesion to saphe- 
nous vein. 
In conclusion, one of the mechanisms by which 
plasma fibrinogen influences the patency of distal vein 
grafts is by stimulating, directly or indirectly, the 
development of vein graft stenosis. 
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